Cushing Syndrome Pharmacotherapy

Therapeutic assessment starts with the cause

Review all oral, injected, inhaled, topical, and locally administered glucocorticoids before assuming endogenous disease. Endogenous hypercortisolism may reflect pituitary ACTH excess, adrenal cortisol production, or ectopic ACTH production. Screening and source localization generally require specialist involvement and should precede prolonged pharmacotherapy decisions. Complications requiring concurrent management include hypertension, diabetes, infection risk, venous thromboembolism, osteoporosis, hypokalemia, psychiatric symptoms, and cardiovascular risk.

Confirm clinically important hypercortisolism and locate the source

Screening is appropriate when characteristic findings accumulate, such as proximal myopathy, wide violaceous striae, easy bruising, poorly controlled hypertension or diabetes, and unexplained osteoporosis. Review glucocorticoid formulations and conditions that can mimic hypercortisolism before interpreting results. Endocrinology commonly uses more than one first-line test, such as late-night salivary cortisol, 24-hour urinary free cortisol, or an overnight dexamethasone suppression test. A random serum cortisol is not a reliable general screening test. After biochemical confirmation, ACTH and targeted imaging/localization distinguish pituitary, adrenal, and ectopic causes (Polomoff et al., 2026).

Exogenous Cushing syndrome: prevent harm during withdrawal

When Cushing syndrome is medication induced, reassess the indication, dose, route, and duration of glucocorticoid exposure. Do not abruptly stop clinically necessary long-term therapy: hypothalamic-pituitary-adrenal (HPA) suppression and recurrence of the underlying disease must both be considered. Patients with Cushingoid features during current or recent glucocorticoid treatment should be presumed at risk for glucocorticoid-induced adrenal insufficiency until appropriately assessed. If the underlying disease is controlled, taper toward a physiologic dose with monitoring and consider steroid-sparing treatment when feasible (Beuschlein et al., 2024; Polomoff et al., 2026).

Taper according to exposure, HPA suppression, and disease activity

Abrupt withdrawal of long-term supraphysiologic prednisone can cause adrenal insufficiency even while Cushingoid features persist. The 2024 joint endocrine guideline recommends approaching a physiologic dose (approximately 4–6 mg/day of prednisone equivalent) before deciding how to discontinue therapy. At that point, either continue a clinically monitored gradual taper or assess recovery using a morning serum cortisol, according to the clinical setting. The original disease, withdrawal symptoms, possible persistent HPA suppression, and intercurrent illness determine the individual plan; a fixed taper schedule is not universally appropriate (Beuschlein et al., 2024).

Endogenous disease: surgery and pharmacotherapy

Curative treatment often depends on addressing the causative lesion surgically. Medical treatment is used when surgery is unsuitable, incompletely effective, delayed, or followed by recurrent disease, and may control hypercortisolism while radiation takes effect. Medication selection depends on speed of required control, tumor location, diabetes, pregnancy potential, hepatic or cardiac risk, drug interactions, and access to monitoring.

Select the purpose of medical therapy explicitly

Medical treatment may bridge to definitive pituitary or adrenal surgery, treat persistent disease after surgery, stabilize severe hypercortisolism before an intervention, or control disease when surgery is not feasible. Choice depends on how urgently cortisol must fall, baseline liver and cardiac risk, pregnancy potential, diabetes severity, electrolyte status, drug access, and whether direct biochemical monitoring is possible. Treat simultaneous infection risk, hyperglycemia, thromboembolism risk, hypertension, psychiatric symptoms, and bone disease; normalizing cortisol alone does not immediately reverse established complications (Polomoff et al., 2026).

Adrenal steroidogenesis inhibitors

A steroidogenesis inhibitor can overcorrect cortisol before symptoms resolve

Osilodrostat inhibits adrenal 11β-hydroxylase. Its November 2025 FDA label covers adults with endogenous Cushing syndrome for whom surgery is not an option or has not been curative. The typical starting dose is 2 mg orally twice daily, with initial titration by 1–2 mg twice daily no more frequently than every two weeks; the labeled maximum is 30 mg twice daily. Correct low potassium and magnesium before treatment and obtain a baseline ECG, repeating it within one week after initiation. Monitor urinary free cortisol using appropriate collections, clinical hypocortisolism, blood pressure, potassium, precursor-related androgen effects and QTc. Initiate at 1 mg twice daily for Child-Pugh B and 1 mg once nightly for Child-Pugh C. Do not use unsupervised titration or assume persistent Cushingoid features mean inadequate suppression (Recordati Rare Diseases Inc., 2025).

Ketoconazole and levoketoconazole reduce cortisol synthesis through inhibition of adrenal steroidogenic enzymes. Hepatic toxicity, drug interactions, and potential QT effects complicate selection. The reference describes levoketoconazole administered in divided oral doses, with careful hepatic assessment and ongoing monitoring. Because inhibition can overshoot, assess for anorexia, nausea, severe fatigue, hypotension, and laboratory evidence of adrenal insufficiency rather than assuming all nonspecific symptoms indicate persistent Cushing syndrome.

Current levoketoconazole (Recorlev) labeling makes liver-test thresholds operational: permanently discontinue if ALT or AST reaches at least five times ULN or reaches at least three times ULN with total bilirubin above twice ULN. For ALT/AST three to less than five times ULN without that bilirubin criterion, interrupt and follow the product-specific monitoring and possible cautious-restart algorithm. Liver tests and QT-risk assessment must be organized before and throughout therapy; do not generalize these exact Recorlev thresholds to all ketoconazole formulations (Recordati Rare Diseases Inc., 2026).

Metyrapone and osilodrostat inhibit 11β-hydroxylase and reduce cortisol synthesis, but precursor accumulation and oversuppression can change the clinical picture. Metyrapone may increase androgenic or mineralocorticoid manifestations; osilodrostat adds important QTc and hypokalemia precautions. Reported osilodrostat dose ranges are not substitutes for a patient-specific initiation and titration plan. Before prescribing or changing dose, coordinate cortisol assessment with symptoms, potassium, blood pressure, ECG/QTc when appropriate, and interaction review; unexplained fatigue, nausea, hypotension, or other features of hypocortisolism call for urgent assessment (Polomoff et al., 2026).

Etomidate can suppress cortisol synthesis when rapid parenteral management is required in critically ill patients unable to take oral agents. It belongs in monitored inpatient care, not outpatient treatment. Steroidogenesis inhibitors can necessitate temporary glucocorticoid replacement after profound cortisol suppression; a planned response to adrenal insufficiency is essential (Polomoff et al., 2026).

Ketoconazole and levoketoconazole: interactions drive safety

These agents inhibit multiple adrenal steroidogenic enzymes. Before treatment, review baseline transaminases, other liver disease, QT-risk medications, and clinically important CYP drug interactions. During titration, reassess cortisol response and symptoms of adrenal insufficiency in parallel with liver tests and electrocardiographic risk when indicated. Medication reconciliation is not optional: interactions can affect anticoagulants, antiarrhythmics, and other high-risk therapies. The specific product schedule and dose ceilings require verification against the prescribed formulation (Polomoff et al., 2026).

Metyrapone and osilodrostat: precursor and cortisol effects

Both inhibit 11-beta-hydroxylase and lower cortisol production. Rising upstream steroid precursors may produce acne, hirsutism, hypertension, hypokalemia, or edema, while excessive suppression can produce hypotension, nausea, fatigue, and adrenal insufficiency. Osilodrostat also requires attention to QT effects and the slower response of laboratory and clinical endpoints after a dose change. Avoid escalating solely because the patient retains some Cushingoid features, which may resolve slowly despite improved cortisol control (Polomoff et al., 2026).

Etomidate: a monitored critical-care option

IV etomidate may rapidly suppress steroidogenesis in severe hypercortisolism when the patient is critically ill, cannot use oral therapy, or requires urgent stabilization before definitive treatment. A specialist-directed subhypnotic infusion requires ICU-level monitoring, careful assessment for sedation and hemodynamic effects, and serial cortisol measurement; the Endocrine Society guideline describes cortisol assessment every 4–6 hours during titration. A protocol must address oversuppression and glucocorticoid rescue or block-and-replace therapy. This is not an outpatient substitute for definitive treatment (Nieman et al., 2015; Polomoff et al., 2026).

Agent selection and monitoring: illustrative dose ranges

The following dose ranges illustrate differences among agents rather than interchangeable prescriptions; selection requires product-specific dose verification, contraindications, drug-interaction review and laboratory monitoring. For clinicians, the more important decision is whether the agent inhibits cortisol synthesis, modulates pituitary ACTH secretion or blocks glucocorticoid receptor activity (Polomoff et al., 2026).

Medication	Chapter 46 dose description	Selection and surveillance
Ketoconazole (oral; off-label for Cushing syndrome)	400–1,200 mg/day, divided	Severe hepatotoxicity risk, CYP interactions, gastric-acidity dependence and QT interactions; specialist-directed off-label use
Levoketoconazole	300–1,200 mg/day total in two doses; labeled initiation 150 mg twice daily, titrate no more often than every 2–3 weeks	Boxed warning: hepatotoxicity and QT prolongation; baseline and serial liver tests, ECG, potassium, magnesium, CYP interactions
Metyrapone (off-label for Cushing syndrome)	500 mg/day–6 g/day, divided every 6–8 hours	Specialist-directed off-label use; monitor cortisol suppression, potassium, blood pressure, androgenic effects and adrenal insufficiency; divide doses three to four times daily.
Osilodrostat	Start 2 mg orally twice daily; maintenance commonly 2–7 mg twice daily in trials; maximum 30 mg twice daily; Child-Pugh B starts 1 mg twice daily and Child-Pugh C starts 1 mg once daily in the evening	QT and potassium; precursor effects; hypocortisolism during titration
Mifepristone	300–1,200 mg/day (illustrative textbook range)	Follow clinical glucose, edema, potassium and BP (not cortisol). Pregnancy contraindication. Limit to 600 mg/day in renal or mild-to-moderate hepatic impairment; with strong CYP3A inhibition do not exceed 900 mg/day, with dose reduction when adding the inhibitor.
Pasireotide	0.3–0.9 mg subcutaneously twice daily; usual initial 0.6 or 0.9 mg twice daily; Child-Pugh B: initial 0.3 and maximum 0.6 mg twice daily	Hyperglycemia, bradycardia/QT, liver tests, potassium/magnesium, gallbladder disease; avoid in Child-Pugh C

Pituitary-directed and receptor-directed treatment

For selected ACTH-secreting pituitary disease, somatostatin analogs such as pasireotide and the dopamine agonist cabergoline may be considered in specialist-directed treatment plans. Pasireotide can aggravate dysglycemia, so preexisting diabetes and glycemic monitoring matter. The glucocorticoid receptor antagonist mifepristone improves manifestations of cortisol activity—particularly hyperglycemia—in selected patients, but does not reliably lower measured cortisol concentrations. Therefore, serum cortisol alone cannot be used to judge biochemical response while receptors are blocked.

Mifepristone changes the monitoring endpoint

For mifepristone, serum cortisol and ACTH do not reliably measure clinical benefit because the medication blocks the glucocorticoid receptor rather than suppressing cortisol synthesis. Monitor glycemia, blood pressure, edema, potassium, weight and symptoms of excess receptor blockade; suspected clinical adrenal insufficiency requires prompt specialist-directed reassessment even when measured cortisol remains elevated. In contrast, osilodrostat, metyrapone and other synthesis inhibitors are evaluated with appropriate cortisol testing in addition to clinical response (Polomoff et al., 2026).

Mifepristone (Korlym) antagonizes the glucocorticoid receptor and is labeled to control hyperglycemia caused by endogenous Cushing syndrome in eligible adults with glucose intolerance or T2DM when surgery is unsuccessful or inappropriate. Initiate 300 mg once daily with a meal and titrate by clinical response, not serum cortisol; the usual maximum is 1,200 mg/day and 20 mg/kg/day. The September 2024 label caps treatment at 600 mg/day in renal impairment or mild-to-moderate hepatic impairment and advises against use in severe hepatic impairment. For a patient already receiving a strong CYP3A inhibitor, begin Korlym at 300 mg/day and titrate, if clinically indicated, to no more than 900 mg/day. When a strong CYP3A inhibitor is added to established Korlym treatment, first reduce Korlym according to the label-specific dose-adjustment table; the permitted later maximum depends on the previous Korlym dose. Pregnancy is contraindicated and must be excluded before treatment and after interruption exceeding 14 days. Correct hypokalemia before initiation and reassess potassium 1–2 weeks after initiation or dose increase, then periodically. Review narrow-therapeutic-index CYP3A substrates and systemic glucocorticoid requirements (Corcept Therapeutics Incorporated, 2024).

Pasireotide and cabergoline: pituitary-targeted compromises

Subcutaneous pasireotide (Signifor) for Cushing disease usually begins at 0.6 mg or 0.9 mg twice daily, adjusted according to response and tolerability. In moderate hepatic impairment (Child-Pugh B), the labeled starting dose is reduced to 0.3 mg twice daily and the maximum is 0.6 mg twice daily; avoid use in Child-Pugh C. Before treatment, obtain fasting glucose or A1c, liver tests, ECG, potassium, magnesium, and gallbladder assessment. Hyperglycemia may worsen substantially and warrants a treatment and monitoring plan. These subcutaneous doses must not be transferred to intramuscular Signifor LAR, which has separate Cushing disease and acromegaly regimens (Recordati Rare Diseases Inc., 2024).

In selected patients with ACTH-dependent Cushing disease, pasireotide or off-label cabergoline may be considered when definitive therapy is unsuccessful or unsuitable. Pasireotide can substantially worsen glycemic control and requires a glucose-monitoring and treatment plan. Cabergoline has less predictable and sometimes waning biochemical efficacy; monitor for dopamine-agonist adverse effects. Compare these strategies with surgery, radiation, steroidogenesis inhibitors, and receptor blockade according to the disease mechanism and treatment goal (Nieman et al., 2015; Polomoff et al., 2026; Recordati Rare Diseases Inc., 2024).

Medication selection: clinical distinctions

Choose the laboratory endpoint that matches the drug

Cortisol synthesis inhibitors such as metyrapone or osilodrostat require monitoring for excessive cortisol suppression and consequent adrenal insufficiency. They also present drug-specific risks: osilodrostat can prolong QTc and contribute to hypokalemia or androgen-related adverse effects, while metyrapone can increase androgenic and mineralocorticoid precursors. Baseline comorbidities and interacting medications determine which toxicities are most consequential.

A prescribing note should name both the therapeutic endpoint and a rescue threshold: for a steroidogenesis inhibitor, track the specific cortisol assay and symptoms that may indicate underproduction; for receptor blockade, follow metabolic and clinical response while assessing potassium, edema, blood pressure, and signs of excessive antagonism. Discuss pregnancy potential and important drug interactions before selecting mifepristone. These are different monitoring frameworks, not interchangeable laboratory algorithms (Polomoff et al., 2026).

For any cortisol-directed regimen, document whether treatment is being used for preoperative stabilization, persistent postoperative disease, or disease that cannot be treated surgically. Specify the drug-specific biochemical and clinical monitoring plan, stopping or rescue criteria for hypocortisolism, and how to obtain urgent evaluation when severe symptoms occur (Polomoff et al., 2026).

Treatment	Principal role	Primary monitoring concern
Levoketoconazole or ketoconazole	Reduce adrenal cortisol synthesis	Hepatic function, interactions, hypocortisolism
Metyrapone or osilodrostat	Block cortisol synthesis via 11β-hydroxylase	Hypocortisolism, electrolytes, potential QT risk
Pasireotide	Pituitary-directed control in selected disease	Hyperglycemia, gallbladder and cardiac effects
Mifepristone	Block glucocorticoid receptor activity	Clinical response, potassium, blood pressure; cortisol is not response marker
Etomidate	Rapid inpatient cortisol control	Close ICU-level clinical and biochemical monitoring

Evaluating response and recognizing treatment failure

Track clinical measures alongside endocrine testing: blood pressure, glucose, weight, muscle strength, edema, potassium, sleep, mood, infection, and metabolic risk. Hormonal monitoring depends on whether the medication lowers cortisol production or blocks its receptor. Assess for relapse after surgical or pharmacologic response. New fatigue, hypotension, dizziness, vomiting, or marked biochemical suppression may signal treatment-induced adrenal insufficiency and requires prompt reassessment.

Distinguish inadequate suppression from treatment-induced adrenal insufficiency

A structured follow-up documents baseline and repeated cortisol testing appropriate to the selected agent, blood pressure, glucose, potassium, weight, edema, muscle strength, mood, sleep, and new infections. A patient whose cortisol falls sharply and develops weakness, vomiting, or hypotension needs urgent assessment for drug-induced hypocortisolism. Conversely, clinical and biochemical relapse can follow initial response; document a defined plan for reassessment rather than relying on an isolated result (Polomoff et al., 2026).

Evaluate the harm of cortisol excess while treating the source

A follow-up plan should identify the assay that reflects the specific mechanism of therapy, the symptoms that mandate urgent reassessment, the anticipated interval to clinical improvement, and how therapy will be adjusted if control is inadequate. In receptor blockade with mifepristone, clinical and metabolic findings are central because measured cortisol is not a reliable marker of blockade effectiveness.

Applied clinical decision-making

Case: urgent control in severe hypercortisolism

A hospitalized patient with severe hypercortisolism has profound hypokalemia, uncontrolled diabetes, and an active infection. Treatment must proceed in parallel: control infection and glucose, correct potassium, assess hemodynamics, and use an appropriate rapidly acting cortisol-lowering approach under specialist oversight. The drug decision cannot be isolated from cardiac monitoring, oral absorption, or the possibility of precipitating adrenal insufficiency.

Case: cortisol remains high after mifepristone

Case: A patient on mifepristone has improved glucose but worsening edema, fatigue and hypokalemia while serum cortisol remains high. Do not interpret the cortisol value alone as treatment failure or automatically increase the dose. Assess potassium and volume, blood pressure, interacting medications, symptoms of glucocorticoid receptor blockade and need for urgent specialty reassessment; the monitoring target must match the drug mechanism (Polomoff et al., 2026).

Counseling by cortisol-treatment mechanism

Patients receiving a steroidogenesis inhibitor need to recognize symptoms of excessive cortisol suppression, including severe weakness, vomiting, dizziness, and hypotension, and must know when to seek urgent assessment. Those receiving mifepristone should understand that a serum cortisol increase is not evidence of medication failure; symptom burden, glucose, blood pressure, potassium, edema, and signs of excessive receptor antagonism determine the response. Review hepatic or QT-related precautions, pregnancy potential, and significant drug interactions according to the selected agent. Complex adverse effects require an explicit specialist contact plan (Polomoff et al., 2026).

High-yield distinctions

Cushing disease is a pituitary subtype of Cushing syndrome. Medication mechanism determines how treatment response and toxicity should be monitored; cortisol levels alone cannot assess all receptor-directed regimens.

Related YourDNP Resources

Pharmacology hub · Cushing syndrome and Cushing disease · Adrenal insufficiency pharmacotherapy · Hyperprolactinemia pharmacotherapy · Diabetes monitoring

---

---

References

Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., Yedinak, C., & Dekkers, O. M. (2024). European Society of Endocrinology and Endocrine Society joint clinical guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency. The Journal of Clinical Endocrinology & Metabolism, 109(7), 1657–1683. https://doi.org/10.1210/clinem/dgae250

Corcept Therapeutics Incorporated. (2024). Korlym (mifepristone) [Prescribing information; revised September 2024]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=542f3fae-8bc8-4f00-9228-e4b66c9ad6a9

Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015). Treatment of Cushing’s syndrome: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(8), 2807–2831. https://doi.org/10.1210/jc.2015-1818

Polomoff, C. M., Chen, J. T., & Dang, D. K. (2026). Adrenal gland disorders. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., pp. 1455–1489). McGraw Hill.

Recordati Rare Diseases Inc. (2024). Signifor (pasireotide) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a09a25fc-a5a3-0c82-e053-2995a90a5d74

Recordati Rare Diseases Inc. (2025). Isturisa (osilodrostat) [Prescribing information; revised November 2025]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3a5ec24-63c3-4d83-b1c0-6c550fbe7ae2

Recordati Rare Diseases Inc. (2026). Recorlev (levoketoconazole) [Prescribing information]. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4c5fead-bc4a-fb02-e053-2a95a90ae4fc